Saffron extract is not a direct GLP-1 receptor agonist like medications such as semaglutide
Pure Formulation Contains no additional additives, ensuring you receive only the beneficial effects of L-Glutathione
Because it activates both, it's often called a "dual agonist." The FDA has described tirzepatide (brand name Zepbound) as the first medication of its kind to activate both of these receptors for weight management, and it was approved for that use in November 2023
In 2016, more than 1.9 billion adults were classified as overweight, including over 650 million individuals living with obesity, a number projected to surpass 1 billion by 2030 [1]
Additionally, some physicians continue to have hesitancy regarding the safety of such medications, which further limits their use
By week 3 or 4 at the starting dose, most users report significant improvement in nausea